BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38905908)

  • 1. Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT).
    Galieni P; Troiani E; Picardi P; Angelini M; Mestichelli F; Dalsass A; Maravalle D; Camaioni E; Bigazzi C; Caraffa P; Ruggieri M; Mazzotta S; Mattioli S; Angelini S
    Leuk Res; 2024 Jun; 143():107541. PubMed ID: 38905908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.
    Li H; Yi SH; Xiong WJ; Liu HM; Lyu R; Wang TY; Liu W; Zhong SZ; Yu Z; Zou DH; Xu Y; An G; Li ZJ; Qiu LG
    Chin Med J (Engl); 2017 Jan; 130(2):135-142. PubMed ID: 28091403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.
    Hu B; Patel KP; Chen HC; Wang X; Luthra R; Routbort MJ; Kanagal-Shamanna R; Medeiros LJ; Yin CC; Zuo Z; Ok CY; Loghavi S; Tang G; Tambaro FP; Thompson P; Burger J; Jain N; Ferrajoli A; Bose P; Estrov Z; Keating M; Wierda WG
    Br J Haematol; 2019 Nov; 187(3):307-318. PubMed ID: 31243771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Cytogenetics Aberrations and
    Muñoz-Novas C; González-Gascón-Y-Marín I; Figueroa I; Sánchez-Paz L; Pérez-Carretero C; Quijada-Álamo M; Rodríguez-Vicente AE; Infante MS; Foncillas MÁ; Landete E; Churruca J; Marín K; Ramos V; Sánchez Salto A; Hernández-Rivas JÁ
    Glob Med Genet; 2024 Jan; 11(1):59-68. PubMed ID: 38348157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages.
    Suárez-Cabrera A; Fiallo-Suárez DV; Stuckey R; Uroz-de la Iglesia ML; Florido Y; Lemes-Castellano A; Perera-Álvarez MÁ; Luzardo-Henríquez H; de la Nuez H; Fernández-Caldas P; de la Iglesia S; Gómez-Casares MT; Bilbao-Sieyro C
    Diagnostics (Basel); 2022 Jul; 12(8):. PubMed ID: 35892513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Lymphocytic Leukemia (CLL) with Borderline Immunoglobulin Heavy Chain Mutational Status, a Rare Subgroup of CLL with Variable Disease Course.
    Angotzi F; Cellini A; Ruocco V; Cavarretta CA; Zatta I; Serafin A; Pravato S; Pagnin E; Bonaldi L; Frezzato F; Facco M; Piazza F; Trentin L; Visentin A
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
    Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
    Mansouri L; Thorvaldsdottir B; Sutton LA; Karakatsoulis G; Meggendorfer M; Parker H; Nadeu F; Brieghel C; Laidou S; Moia R; Rossi D; Catherwood M; Kotaskova J; Delgado J; Rodríguez-Vicente AE; Benito R; Rigolin GM; Bonfiglio S; Scarfo L; Mattsson M; Davis Z; Gogia A; Rani L; Baliakas P; Foroughi-Asl H; Jylhä C; Skaftason A; Rapado I; Miras F; Martinez-Lopez J; de la Serna J; Rivas JMH; Thornton P; Larráyoz MJ; Calasanz MJ; Fésüs V; Mátrai Z; Bödör C; Smedby KE; Espinet B; Puiggros A; Gupta R; Bullinger L; Bosch F; Tazón-Vega B; Baran-Marszak F; Oscier D; Nguyen-Khac F; Zenz T; Terol MJ; Cuneo A; Hernández-Sánchez M; Pospisilova S; Mills K; Gaidano G; Niemann CU; Campo E; Strefford JC; Ghia P; Stamatopoulos K; Rosenquist R
    Leukemia; 2023 Feb; 37(2):339-347. PubMed ID: 36566271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia.
    Morabito F; Tripepi G; Moia R; Recchia AG; Boggione P; Mauro FR; Bossio S; D'Arrigo G; Martino EA; Vigna E; Storino F; Fronza G; Di Raimondo F; Rossi D; Condoluci A; Colombo M; Fais F; Fabris S; Foa R; Cutrona G; Gentile M; Montserrat E; Gaidano G; Ferrarini M; Neri A
    Front Oncol; 2021; 11():684621. PubMed ID: 34408978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
    Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
    Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the
    Baldoni S; Del Papa B; De Falco F; Dorillo E; Sorrentino C; Rompietti C; Adamo FM; Nogarotto M; Cecchini D; Mondani E; Silva Barcelos EC; Moretti L; Mameli MG; Fabi B; Sorcini D; Stella A; Giancola R; Guardalupi F; Ulbar F; Plebani S; Guarente V; Rosati E; Di Nicola M; Marchioni M; Di Ianni M; Sportoletti P
    Front Oncol; 2021; 11():668573. PubMed ID: 34123837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.
    Gladstone DE; Swinnen L; Kasamon Y; Blackford A; Gocke CD; Griffin CA; Meade JB; Jones RJ
    Leuk Lymphoma; 2011 Oct; 52(10):1873-81. PubMed ID: 21851216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia.
    Hojjat-Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Mellstedt H; Shokri F; Rabbani H
    Cancer Sci; 2009 Dec; 100(12):2346-53. PubMed ID: 19824994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.
    Molica S; Shanafelt TD; Giannarelli D; Gentile M; Mirabelli R; Cutrona G; Levato L; Di Renzo N; Di Raimondo F; Musolino C; Angrilli F; Famà A; Recchia AG; Chaffee KG; Neri A; Kay NE; Ferrarini M; Morabito F
    Am J Hematol; 2016 Nov; 91(11):1090-1095. PubMed ID: 27465919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of four prognostic scoring system in patients with early asymptomatic chronic lymphocytic leukemia patients].
    Sha YQ; Shen H; Wu W; Xia Y; Miao Y; Cao L; Wang L; Fan L; Xu W; Li JY; Zhu HY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):834-839. PubMed ID: 34788923
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
    Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
    Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
    International CLL-IPI working group
    Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
    Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
    Sandoval-Sus JD; Chavez JC; Dalia S; Naqvi SMH; Talati C; Nodzon L; Kharfan-Dabaja MA; Pinilla-Ibarz J
    Leuk Lymphoma; 2018 Jan; 59(1):59-68. PubMed ID: 28641468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.